MCID: CNN001
MIFTS: 44

Cannabis Dependence

Categories: Mental diseases

Aliases & Classifications for Cannabis Dependence

Summaries for Cannabis Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of cannabis despite problems related to use of the substance.

MalaCards based summary : Cannabis Dependence, also known as marijuana abuse, is related to alcohol dependence and disease of mental health. An important gene associated with Cannabis Dependence is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are Neuroscience and GABAergic synapse. The drugs Dronabinol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lung, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is defined in the... more...

Related Diseases for Cannabis Dependence

Diseases related to Cannabis Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 alcohol dependence 30.0 CNR1 COMT FAAH
2 disease of mental health 29.4 CNR1 COMT HCRT NRG1
3 major depressive disorder 28.9 ABCB1 COMT HCRT
4 cannabis abuse 12.0
5 pain agnosia 10.2 CNR1 FAAH
6 depression 10.2
7 agnosia 10.2 CNR1 FAAH
8 schizophrenia 10.1
9 drug dependence 10.1 CNR1 PENK
10 schizophreniform disorder 10.1 COMT NRG1
11 somatoform disorder 10.1 COMT FAAH
12 bone cancer 10.1 CNR1 PENK
13 alcohol abuse 10.0 CNR1 FAAH
14 anxiety 10.0
15 eating disorder 10.0 CNR1 COMT
16 hallucinogen dependence 10.0 CNR1 FAAH PENK
17 bipolar i disorder 10.0 COMT NRG1
18 kleine-levin hibernation syndrome 9.9 COMT HCRT
19 cocaine dependence 9.9
20 polysubstance abuse 9.9 CNR1 COMT FAAH
21 post-traumatic stress disorder 9.9 CNR1 COMT FAAH
22 myocardial infarction 9.9
23 membranous nephropathy 9.9
24 acute myocardial infarction 9.9
25 glomerulonephritis 9.9
26 atrial fibrillation 9.9
27 epilepsy 9.9
28 human immunodeficiency virus infectious disease 9.9
29 cerebrovascular disease 9.9
30 specific developmental disorder 9.9 CNR1 COMT
31 autoimmune encephalitis 9.9 CNR1 FAAH HCRT
32 opioid addiction 9.8 ABCB1 COMT
33 cognitive function 1, social 9.8
34 borderline personality disorder 9.8
35 personality disorder 9.8
36 psychotic disorder 9.8
37 opiate dependence 9.8
38 substance abuse 9.8
39 migraine with or without aura 1 9.8 CNR1 COMT HCRT
40 parkinson disease, late-onset 9.7 CNR1 COMT HCRT
41 body mass index quantitative trait locus 11 9.5 CNR1 FAAH HCRT

Graphical network of the top 20 diseases related to Cannabis Dependence:



Diseases related to Cannabis Dependence

Symptoms & Phenotypes for Cannabis Dependence

MGI Mouse Phenotypes related to Cannabis Dependence:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.5 ABCB1 CNR1 COMT FAAH HCRT MGLL
2 homeostasis/metabolism MP:0005376 9.17 ABCB1 CNR1 COMT FAAH HCRT MGLL

Drugs & Therapeutics for Cannabis Dependence

Drugs for Cannabis Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 464)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1972-08-3 16078
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
3
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
4
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 52485-79-7 644073 40400
6
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
7
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 446220 5760
8
leucovorin Approved Phase 4,Phase 2 58-05-9 143 6006
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
10
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
11
Clozapine Approved Phase 4,Not Applicable 5786-21-0 2818
12
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 89594 942
13
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
14
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
15
Bupropion Approved Phase 4,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Budesonide Approved Phase 4 51333-22-3 5281004 63006
18
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
19
Ledipasvir Approved Phase 4 1256388-51-8 67505836
20
Lixisenatide Approved Phase 4 320367-13-3
21
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
22
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
23
Lorazepam Approved Phase 4,Phase 1 846-49-1 3958
24
Progesterone Approved, Vet_approved Phase 4,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
25
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 1 113-45-1 4158
26
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
27
Ondansetron Approved Phase 4 99614-02-5 4595
28
Haloperidol Approved Phase 4 52-86-8 3559
29
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
30
Physostigmine Approved, Investigational Phase 4 57-47-6 5983
31
Cefazolin Approved Phase 4 25953-19-9 33255 656510
32
Cefdinir Approved Phase 4 91832-40-5 6915944
33
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
34
Sulfamethoxazole Approved Phase 4 723-46-6 5329
35
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
36
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
37
Aripiprazole Approved, Investigational Phase 4,Phase 2 129722-12-9 60795
38
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
40 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Olive Phase 4,Phase 1,Phase 2
47 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Cannabinoid Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hallucinogens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 780)
# Name Status NCT ID Phase Drugs
1 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
2 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
3 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
4 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
5 Clozapine for Cannabis Use in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
6 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
7 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
8 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
9 Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
10 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
11 Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section Completed NCT02780245 Phase 4 Tranexamic Acid
12 The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis Completed NCT02696850 Phase 4 Budesonide;Saline alone
13 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4 Marinol;Placebo
14 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Completed NCT02347345 Phase 4 Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
15 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes Completed NCT00510276 Phase 4 Atomoxetine hydrochloride;Placebo
16 Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes Completed NCT02049034 Phase 4
17 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
18 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Recruiting NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
19 Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain Recruiting NCT03337503 Phase 4 THC and CDB in a 1 to 1 ratio;Experimental: THC and CBD in a 1 to 2 ratio;High CBD with trace THC oil
20 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) Recruiting NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
21 Brexpiprazole Study Recruiting NCT03526354 Phase 4 Brexpiprazole
22 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome Recruiting NCT03090620 Phase 4 Physostigmine;Lorazepam
23 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4 Progesterone;Placebo
24 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
25 Cannabinoids for Pain Control During Medical Abortion Active, not recruiting NCT03604341 Phase 4 Dronabinol 5mg Cap
26 Strong African American Families STEPS Project Active, not recruiting NCT03590132 Phase 4
27 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
28 Effects of THC and Alcohol on Driving Performance Not yet recruiting NCT03555968 Phase 4 THC 0;THC 125;THC 250
29 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
30 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4 Atomoxetine
31 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
32 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Withdrawn NCT01155544 Phase 4
33 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
34 Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use Unknown status NCT00547963 Phase 2, Phase 3
35 CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS Unknown status NCT00673647 Phase 3
36 Anesthetic Premedication With a Cannabis Extract (Cannapremed) Unknown status NCT02283281 Phase 2, Phase 3 Tetrahydrocannabinol;Acetaminophen;Midazolam;Dummy oromucosal spray
37 Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients Unknown status NCT02802540 Phase 2, Phase 3 Nabilone;Placebo
38 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
39 Combined Pharmacotherapy for Cannabis Dependency Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
40 Facilitating the Behavioral Treatment of Cannabis Use Disorder Completed NCT02946489 Phase 2, Phase 3 CI-581a
41 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
42 Nabilone & Marijuana Addiction Completed NCT01025700 Phase 2, Phase 3 Cesemat
43 Teen Marijuana Check-Up Completed NCT01109563 Phase 3
44 Vaporized Cannabis and Spinal Cord Injury Pain Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
45 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
46 A Brief Marijuana Intervention for Adolescent Women - 1 Completed NCT00227864 Phase 3
47 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
48 Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
49 A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury Completed NCT01606202 Phase 3 GW-1000-02;Placebo
50 A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin Completed NCT01606176 Phase 3 GW-1000-02;Placebo

Search NIH Clinical Center for Cannabis Dependence

Cochrane evidence based reviews: marijuana abuse

Genetic Tests for Cannabis Dependence

Anatomical Context for Cannabis Dependence

MalaCards organs/tissues related to Cannabis Dependence:

42
Testes, Brain, Lung, Liver, Colon, Breast, Spinal Cord

Publications for Cannabis Dependence

Articles related to Cannabis Dependence:

(show top 50) (show all 188)
# Title Authors Year
1
Pharmacotherapies for cannabis dependence. ( 30687936 )
2019
2
Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. ( 30747847 )
2019
3
Cannabis Dependence or Abuse in Kidney Transplantation: One Perspective. ( 30747855 )
2019
4
The limitations associated with measuring cannabis dependence, a response to Budney and colleagues. ( 30927076 )
2019
5
Genome-wide association study identifies a novel locus for cannabis dependence. ( 29112194 )
2018
6
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. ( 29385147 )
2018
7
Open-label pilot study of injectable naltrexone for cannabis dependence. ( 29420073 )
2018
8
The Wrong Kind of Connections: Cannabis Dependence and Subcortical Hyperconnectivity. ( 29486861 )
2018
9
Subcortical Local Functional Hyperconnectivity in Cannabis Dependence. ( 29486870 )
2018
10
Alteration to hippocampal volume and shape confined to cannabis dependence: a multi-site study. ( 30022573 )
2018
11
Whole genome sequence study of cannabis dependence in two independent cohorts. ( 28111843 )
2018
12
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. ( 30239074 )
2018
13
Association between increased EEG signal complexity and cannabis dependence. ( 29132831 )
2017
14
Decisional balance and processes of change in community-recruited with moderate-high versus mild severity of cannabis dependence. ( 29206230 )
2017
15
Deficits in striatal dopamine release in cannabis dependence. ( 27001613 )
2017
16
Social cognitive predictors of treatment outcome in cannabis dependence. ( 27883947 )
2017
17
Treatment seeking in cannabis dependence: The role of social cognition. ( 27894043 )
2017
18
Differential effects of cannabis dependence on cortical inhibition in patients with schizophrenia and non-psychiatric controls. ( 27964871 )
2017
19
S100A10 identified in a genome-wide gene × cannabis dependence interaction analysis of risky sexual behaviours. ( 28418321 )
2017
20
Greater Prevalence of Proposed ICD-11 Alcohol and Cannabis Dependence Compared to ICD-10, DSM-IV, and DSM-5 in Treated Adolescents. ( 28667763 )
2017
21
Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. ( 28921814 )
2017
22
Acute myocardial infarction and ischemic stroke coexistence due to marijuana abuse in an adolescent. ( 27389155 )
2016
23
Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study. ( 28008372 )
2016
24
Psychosocial Determinants of Cannabis Dependence: A Systematic Review of the Literature. ( 26551358 )
2016
25
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. ( 26685701 )
2016
26
Genome-wide Significant Associations for Cannabis Dependence Severity: Relevance to Psychiatric Disorders. ( 27027914 )
2016
27
Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks. ( 27028160 )
2016
28
Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series. ( 27261670 )
2016
29
Anxiety Sensitivity and Distress Intolerance as Predictors of Cannabis Dependence Symptoms, Problems, and Craving: The Mediating Role of Coping Motives. ( 27797690 )
2016
30
Small Molecule Detection in Saliva Facilitates Portable Tests of Marijuana Abuse. ( 27434697 )
2016
31
Marijuana Abuse in Singapore. ( 27922141 )
2016
32
Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. ( 25240105 )
2015
33
Risk-taking in schizophrenia and controls with and without cannabis dependence. ( 25467541 )
2015
34
Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. ( 25543035 )
2015
35
Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. ( 25622777 )
2015
36
Maintenance Check-ups Following Treatment for Cannabis Dependence. ( 25922136 )
2015
37
Concordance of Direct and Indirect Measures of Medication Adherence in A Treatment Trial for Cannabis Dependence. ( 26028133 )
2015
38
Three-Year Course of Cannabis Dependence and Prediction of Persistence. ( 26044258 )
2015
39
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. ( 26213314 )
2015
40
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. ( 26386827 )
2015
41
Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. ( 26595473 )
2015
42
The impacts of marijuana dispensary density and neighborhood ecology on marijuana abuse and dependence. ( 26154479 )
2015
43
Cortical thinness and volume differences associated with marijuana abuse in emerging adults. ( 26249265 )
2015
44
Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. ( 24067260 )
2014
45
Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. ( 24359507 )
2014
46
Baclofen in the management of cannabis dependence syndrome. ( 24490032 )
2014
47
Imaging dopamine transmission parameters in cannabis dependence. ( 24513022 )
2014
48
Different dopaminergic abnormalities underlie cannabis dependence and cannabis-induced psychosis. ( 24560431 )
2014
49
Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. ( 24628797 )
2014
50
Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment. ( 24793365 )
2014

Variations for Cannabis Dependence

Expression for Cannabis Dependence

Search GEO for disease gene expression data for Cannabis Dependence.

Pathways for Cannabis Dependence

GO Terms for Cannabis Dependence

Cellular components related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GABA-ergic synapse GO:0098982 8.96 CNR1 NRG1
2 axon GO:0030424 8.92 CNR1 COMT NRG1 PENK

Biological processes related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.58 HCRT NRG1 PENK
2 locomotory behavior GO:0007626 9.43 NRG1 PENK
3 sensory perception of pain GO:0019233 9.37 CNR1 PENK
4 response to nicotine GO:0035094 9.32 CNR1 PENK
5 regulation of sensory perception of pain GO:0051930 9.26 COMT MGLL
6 response to morphine GO:0043278 9.16 CNR1 PENK
7 arachidonic acid metabolic process GO:0019369 8.96 FAAH MGLL
8 response to lipopolysaccharide GO:0032496 8.8 CNR1 COMT PENK

Molecular functions related to Cannabis Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 HCRT PENK
2 acylglycerol lipase activity GO:0047372 8.62 FAAH MGLL

Sources for Cannabis Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....